1.
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease
by Chen, Jack J., PharmD, BCPS, CGp
Clinical therapeutics, 2007, Vol.29 (9), p.1825-1849
2.
Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline
by Degli Esposti, Luca
Neurological sciences, 2015, Vol.37 (2), p.227-234
3.
A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents
by DelBello, Melissa P.
Journal of child and adolescent psychopharmacology, 2014, Vol.24 (6), p.311-317
4.
Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease
by Yoritaka, Asako
European neurology, 2016, Vol.76 (1-2), p.35-39
5.
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors
by Henchcliffe, Claire
Expert review of neurotherapeutics, 2005, Vol.5 (6), p.811-821
6.
Transdermal selegiline and intravenous cocaine: safety and interactions
by HOUTSMULLER, Elisabeth J
Psychopharmacologia, 2004, Vol.172 (1), p.31-40
7.
Transdermal Selegiline in Patients Receiving Electroconvulsive Therapy
by Horn, Pamela J., M.D
Psychosomatics (Washington, D.C.), 2011, Vol.51 (2), p.176-178
8.
Effects of selegiline (l-deprenyl) during smoking and short-term abstinence
by HOUTSMULLER, Elisabeth J
Psychopharmacologia, 2002, Vol.163 (2), p.213-220
9.
Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder
by Rubinstein, Suzanne
Journal of child and adolescent psychopharmacology, 2006, Vol.16 (4), p.404-415
10.
Selegiline orally disintegrating tablets for the treatment of Parkinson's disease
by Lew, Mark F
Expert review of neurotherapeutics, 2005, Vol.5 (6), p.705-712
11.
Clinical and [18F] dopa PET findings in early Parkinson's disease
by Morrish, P K
Journal of neurology, neurosurgery and psychiatry, 1995, Vol.59 (6), p.597-600
12.
Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial
by Mohammadi, Mohammad Reza
Journal of child and adolescent psychopharmacology, 2004, Vol.14 (3), p.418-425
13.
Use of Transdermal Selegiline in Pregnancy and Lactation: A Case Report
by Bauer, Rebecca L
Psychosomatics (Washington, D.C.), 2017, Vol.58 (4), p.450-452
14.
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease
by HAAPANIEMI, Tarja H
Journal of neurology, 2000, Vol.247 (11), p.868-874
15.
Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy
by Hasegawa, Masanori
Forensic science international, 1999, Vol.101 (2), p.95-106
16.
Practical importance of neuroprotection in Parkinson's disease
by Riederer, P
Journal of neurology, 2002, Vol.249 Suppl 3, p.III/53-1
17.
Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease
by Ito, D
Journal of neurology, 2001, Vol.248 (6), p.533-534
18.
Parkinson's disease therapy: treatment of early and late disease
by Jankovic, J
Chinese medical journal, 2001, Vol.114 (3), p.227-234
19.
Moclobemide and selegeline in the treatment of depression in Parkinson’s disease
by STEUR, ERNST N H JANSEN
Journal of neurology, neurosurgery and psychiatry, 1997, Vol.63 (4), p.547-547
20.
Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease
by ALAFUZOFF, I
European journal of clinical pharmacology, 2000, Vol.55 (11-12), p.815-819
